Daniel Zlatin, Author at Waldenstrom's Macroglobulinemia Foundation of Canada

May Newsletter – A Tribute to Dave Johnston

2023-05-31T21:06:47-04:00

Dave Johnston’s long acquaintance with WM and the WMFC David R. Johnston - Life with Waldenstrom's Macroglobulinemia In May 1998 David attributed his unexplained weight loss to the considerable physical effort he put in over several weeks cleaning up fallen branches on the grounds of his beloved family cottage which, along with huge swaths of Eastern Ontario and Western Quebec, had been hit by a catastrophic ice storm a few months earlier. However, around the same time, David's GP observed that his haemoglobin had dropped below normal levels to 122, and proceeded to look for a possible cause. Unable to find [...]

May Newsletter – A Tribute to Dave Johnston2023-05-31T21:06:47-04:00

Current Canadian Research in WM

2023-04-20T17:17:57-04:00

The WMFC and IWMF are co-funding cutting edge WM research at the Odette Cancer Centre, Sunnybrook Hospital, in Toronto. Two major WM events are occurring at Sunnybrook. The first is Dr. Neil Berinstein’s pan-Canadian BRAWM trial that is headquartered at Sunnybrook. This exciting trial combines Bendamustine, Rituximab and the BTK inhibitor, Acalabrutinib (BRA) for first line treatment in WM. Within a few months it is expected that the trial will have filled all 59 openings in this coast-to-coast trial. The second event arises from the first. Patients in the BRAWM trial have blood and marrow samples taken before, during and after [...]

Current Canadian Research in WM2023-04-20T17:17:57-04:00

Diagnostic and Response Criteria: IWWM-11 Consensus Panel 4

2023-04-20T08:15:56-04:00

Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for diagnosis and response assessment. Their report is available here.

Diagnostic and Response Criteria: IWWM-11 Consensus Panel 42023-04-20T08:15:56-04:00

Management of WM-Related Amyloidosis: IWWM-11 Consensus Panel 6

2023-04-18T21:09:54-04:00

Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM). Their report is available here.

Management of WM-Related Amyloidosis: IWWM-11 Consensus Panel 62023-04-18T21:09:54-04:00

Bing-Neel Syndrome Update with Dr. Shayna Sarosiek, April 2023

2023-04-16T18:01:56-04:00

Dr. Shayna Sarosiek of Dana-Farber Cancer Institute provided an update on Bing-Neel. This presentation was given to two IWMF support group meetings in April 2023. You can view it here. From IWMF Bing-Neel Co-Leader & Lifeline Volunteer, Julie Davidson: "The Bing-Neel Support Group just had our Spring meeting. We featured a wonderfully informative video by Dr. Shayna Sarosiek, senior physician at the Dana-Farber Cancer Institute’s Bing Center for Waldenstrom’s Macroglobulinemia. To be included on the group mailing list, or just to talk to someone about Bing-Neel Syndrome, contact Julie Davidson, IWMF Lifeline Volunteer for Bing-Neel at jefdavidson@icloud.com.

Bing-Neel Syndrome Update with Dr. Shayna Sarosiek, April 20232023-04-16T18:01:56-04:00

Clinical Trial Priorities for WM: IWWM-11 Consensus Panel 7

2023-04-15T17:13:28-04:00

Consensus Panel 7 (CP7) of the 11th International Workshop on WM was convened to examine the current generation of completed and ongoing clinical trials involving novel agents, consider updated data on WM genomics, and make recommendations on the design and prioritization of future clinical trials. Their report is available here.

Clinical Trial Priorities for WM: IWWM-11 Consensus Panel 72023-04-15T17:13:28-04:00

COVID-19 Prophylaxis and Management: IWWM-11 Consensus Panel 5

2023-04-15T17:08:34-04:00

Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis and management in patients with Waldenstrom's Macroglobulinemia (WM). Their report is available here.

COVID-19 Prophylaxis and Management: IWWM-11 Consensus Panel 52023-04-15T17:08:34-04:00

Recommendations for Molecular Diagnosis in WM: IWWM-11 Consensus Panel 3

2023-04-15T17:06:15-04:00

Consensus Panel 3 (CP3) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular necessities and best way to access the minimum data required for a correct diagnosis and monitoring. Their report is available here.

Recommendations for Molecular Diagnosis in WM: IWWM-11 Consensus Panel 32023-04-15T17:06:15-04:00

Management of Relapsed or Refractory WM Patients: IWWM-11 Consensus Panel 2

2023-04-15T17:02:41-04:00

The Consensus Panel 2 (CP2) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) has reviewed and incorporated current data to update the recommendations for treatment approaches in patients with relapsed or refractory WM (RRWM). Their report is available here.

Management of Relapsed or Refractory WM Patients: IWWM-11 Consensus Panel 22023-04-15T17:02:41-04:00

Management of Symptomatic, Treatment-Naïve Patients: IWWM-11 Consensus Panel 1

2023-04-15T16:59:59-04:00

Consensus Panel 1 (CP1) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naïve patients with WM. Their report is available here.

Management of Symptomatic, Treatment-Naïve Patients: IWWM-11 Consensus Panel 12023-04-15T16:59:59-04:00

DRZ

About Daniel Zlatin